ArticleFrontiers in immunology2025
Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunochemotherapy has been approved as first-line treatment for extensive-stage small cell lung cancer. However, second-line treatment options and whether continuous immunotherapy will improve clinical outcome are still controversial. This multi-center retrospective study aimed to investigate the efficacy of continuous immunotherapy for the patients who suffered progression from first-line immunochemotherapy. Methods: We retrospectively reviewed the medical records of patients with extensive-stage small cell lung cancer treated with first-line immunochemotherapy in three major medical centers in Shandong Province. The patients enrolled achieved disease control during first-line immunochemotherapy but subsequently suffered disease progression. Results: From January 2020 to December 2024, a total of 354 patients treated with first-line immunochemotherapy were enrolled. The first-line progression free survival was 6.60 (95%CI: 6.28-6.92) months. A total of 206 patients were enrolled to compare the efficacy of second-line therapies, including chemotherapy alone (C, 40 cases), chemotherapy + anti-angiogenic therapy (C+A, 17 cases), immunochemotherapy (I+C, 122 cases), immunotherapy + anti-angiogenic therapy (I+A, 11 cases) and immunochemotherapy + anti-angiogenic therapy (I+C+A, 16 cases). Therein, I+C+A group obtained the longest second-line progression free survival of 4.60 (95%CI: 2.71-6.50) months. The second-line progression free survival of I+C group was also longer than that of the C group (3.50, 95%CI: 3.07-3.93 vs 2.33, 95%CI: 1.66-3.01). Regarding overall survival, I+A group achieved the longest overall survival of 22.00 (95%CI: 11.39-32.61) months compared with 19.53 (95%CI: 16.81-22.26) months for I+C group. However, there were no statistical differences in second-line progression free survival and overall survival among the groups. In terms of safety, the rates of adverse events in the I+C and C groups were not statistically significant. Conclusions: Continuous immunotherapy beyond progression in extensive-stage small cell lung cancer shows the trend of prolonging second-line progression free survival, but does not improve the overall survival. Additionally, in the second-line treatment, chemotherapy remains an important cornerstone therapy and anti-angiogenic agent containing strategy may potentially improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.